Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Glucose Metabolism Disorders

Glucose Metabolism Disorders

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Glucose Metabolism Disorders

14 trials tracked for Glucose Metabolism Disorders: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 22 citations.

14Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 3 Phase 1 2 Other / NA 6
  1. Phase 3 A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both Completed · 22 cited
  2. Phase 3 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes Completed · 6 cited
  3. Phase 3 A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes Completed
  4. Phase 2 Soluble Epoxide Hydrolase Inhibition and Insulin Resistance Completed
  5. Phase 2 Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) Completed
  6. Phase 2 Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes Completed
Show 8 more trials
  1. Phase 1 Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females Completed
  2. Phase 1 Aldosterone and the Metabolic Syndrome Completed
  3. N/A Spectrophon LTD Glucometry Monitor Accuracy Completed
  4. N/A Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform Completed
  5. N/A Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes Completed
  6. N/A Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study Completed
  7. N/A Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes Completed
  8. N/A Effect of NMN Supplementation on Organ System Biology Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Glucose Metabolism Disorders: what the trials found

New evidence indicates that placebo interventions in specific cohorts showed changes in muscle insulin sensitivity (19.0; 13.5, p=0.05) and variations in glucose tolerance (-9.0; 14, p=0.05) 1.

Tirzepatide demonstrated significant reductions in HbA1c levels across multiple doses. Pooled doses of 5 mg and 10 mg resulted in a mean reduction of -2.03 to -0.23 (p=<0.001), with individual doses of 5 mg, 10 mg, and 15 mg showing reductions of -1.90, -2.16, and -0.23 respectively (p=<0.001) 2. Tirzepatide at 10 mg or 15 mg showed mean HbA1c reductions of -26.1, -25.9, and -9.96 (p=<0.001), while the 5 mg dose showed a reduction of -23.0; -9.96 (p=<0.001). These doses were also associated with significant reductions in body weight 3.

Dulaglutide was shown to reduce HbA1c by -1.53 and -1.25 at week 26, and -1.50 and -1.19 at week 52 (p=<0.001) 4. However, the percentage of patients achieving specific HbA1c targets (<6.5% or <7.0%) did not reach statistical significance (p=0.560) 4.

Placebo trials showed no statistically significant changes in Glycosylated Hemoglobin (HbA1c) at day 29 and 50 (p=0.419), nor significant changes in Fructosamine levels (p=0.663) or 1,5 Anhydroglucitol levels (p=0.387) 9.

Recent results — preliminary, needs further review

  • The Endogenex Device was evaluated in a small cohort (N=20) 10.

For the clinician treating this condition

  • Tirzepatide is associated with significant reductions in HbA1c across multiple dosages and concurrent reductions in body weight 3.
  • Dulaglutide provides consistent, statistically significant reductions in HbA1c over 52 weeks, though reaching specific target thresholds was not significantly different across groups 4.
  • Placebo interventions in certain studies showed no significant impact on Glycosylated Hemoglobin or related markers like Fructosamine and 1,5 Anhydroglucitol 9.

AI synthesis of 6 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.